THE WIRE · № 64966
TuHURA Biosciences Receives Key U.S. Patent for its Groundbreaking Delta Opioid Receptor (DOR) Antibody Drug Conjugate (ADC) Technology
01 THE MACHINE READ
WHY IT MATTERS.
Patent grant strengthens IP protection for an early-stage immuno-oncology platform, though commercial impact remains distant.
Small-cap biotech secures ADC platform patent
Clinical trial progress or partnership deals
Phase 3 failure or financing needs
FULL DISPATCH
Patent discloses uses beyond ADCs, including autologous or allogeneic adoptive cellular immunotherapies like CAR-T, Tregs or TIL cell therapies TAMPA, Fla., Oct. 5, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company...
02 THE STORY SO FAR
THE RECORD, IN ORDER.
STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.
03 WHO'S INVOLVED
ENTITIES ON FILE.
04 RECEIPTS
THE SOURCE RECORD.
1 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
Lilly to present new data across its dermatology portfolio with 21 presentations at Fall Clinical 2026, in pursuit of advancing care for chronic skin conditions2026-10-05 11:50 UTC
Russia plague: What we know about the suspected case reportedly linked to a lab worker’s death2026-10-05 12:00 UTC
International Brain Health Coalition Launches to Put Proven Strategies Into Action2026-10-05 12:02 UTC
The Pharmacy Budget Trap: SHARx Warns Discounts Alone Cannot Control Total Spending2026-10-05 12:08 UTC
Consano Bio Raises More Than $15 Million in Oversubscribed Financing to Advance C-1101 in Chronic Painful Lumbosacral Radiculopathy (Chronic Sciatica)2026-10-05 12:10 UTC
Anixa Biosciences Announces First Case of Stable Disease for Three Months in Ovarian Cancer CAR-T Clinical Trial2026-10-05 12:15 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.